Kimberly-Clark wins EU approval for Kenvue deal after divestment commitments

Traders Union
All News
Geopolitics & Trade
Kimberly-Clark Kenvue EU approval

Highlights

European Commission approves Kimberly-Clark's acquisition of Kenvue, conditional on full divestment of its EEA feminine hygiene brands including Kotex, Camelia, and Record.
Competition concerns are addressed by selling the entire feminine hygiene business, including intellectual property and staff, to Dilek Gıda Üretim ve Pazarlama Ticaret A.Ş., which regulators find financially and operationally suitable.
The commitments remove horizontal overlap in EEA feminine hygiene markets, with an independent trustee supervising remedy implementation and ensuring long-term market competition.

Competition remedies and approved divestment buyer

As reported by European Commission, the clearance under the EU Merger Regulation is conditional on Kimberly-Clark fully implementing commitments designed to resolve competition concerns linked to the transaction.

The Commission says its review found the deal, as first notified, would reduce competition in tampon supply markets, particularly in Czechia, Estonia and Slovakia, where only a limited number of suppliers are already active. Regulators conclude that the merger would remove an important competitor in those markets.

To address those concerns, Kimberly-Clark commits to divest all of its tampon and other feminine hygiene brands in the European Economic Area, including related intellectual property rights, know-how, key employees and business relationships. The brands covered by the package are Kotex, including the Lidie sub-brand, Camelia and Record.

The Commission also approves Dilek Gıda Üretim ve Pazarlama Ticaret A.Ş. as the purchaser of the divested business. After reviewing Dilek's business plan with support from an independent adviser, regulators determine that the company has the financial resources and operational expertise to maintain and develop the business as an active competitive force.

Merger review timeline and wider market impact

The commitments remove the horizontal overlap between Kimberly-Clark's and Kenvue's activities in the EEA, leading the Commission to conclude that the transaction, as modified, no longer raises competition concerns. An independent trustee monitors implementation of the remedies under the Commission's supervision.

The transaction is notified to the Commission on 25 August 2026. The case proceeds through a Phase I review, which generally lasts 25 working days, but extends by 10 additional working days when remedies are offered at that stage, as happens in this case.

Kimberly-Clark operates globally in personal care products for personal, business and industrial use, with brands including Huggies and Kotex. Kenvue manufactures and supplies consumer health products, with brands including Listerine, Nicorette, Neutrogena and o.b, making the ruling relevant for consumer goods and healthcare markets across the EEA.

In our earlier coverage of Mexico’s planned Volaris–Viva Aerobus tie-up, we explained that the country’s antitrust authority was expected to clear the deal before the end of 2026, but only with conditions to protect competition. The piece highlighted concerns about higher market concentration on overlapping routes and noted potential requirements to keep fares low, limit layoffs, and largely maintain existing route networks.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.